| Chemical Properties | Back Directory | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMSO: ≥ 24 mg/mL (12.95 mM) | [form ]
Solid | [color ]
White to light yellow | [Water Solubility ]
Water: 50 mg/mL (26.98 mM) | [InChIKey]
PEXPCJWLNBNBNT-HHJXNUJUNA-N |
| Hazard Information | Back Directory | [Uses]
Dalbavancin hydrochloride (MDL-63397 hydrochloride) is a semisynthetic lipoglycopeptide antibiotic with potent bactericidal activity against Gram-positive bacteria. Dalbavancin hydrochloride inhibits Staphylococcus aureus and Bacillus anthracis with MIC90s of 0.06 μg/mL and 0.25 μg/mL, respectively[1][2]. | [Biological Activity]
Dalbavancin hydrochloride(MDL-63397 hydrochloride) is a semi-synthetic lipoglycopeptide antibiotic with potent bactericidal activity against Gram-positive bacteria. Dalbavancin hydrochloride inhibits Staphylococcus aureus and Bacillus anthracis with MIC90 of 0.06 μg/mL and 0.25 μg/mL, respectively. | [in vitro]
Dalbavancin is a parenterally administered semisynthetic lipoglycopeptide developed to combat infections caused by resistant gram-positive pathogens. Dalbavancin exhibits potent in vitro bactericidal activity against gram-positive pathogens including S. aureus (MRSA ), VISA, and non-VanA strains of VRE. Dalbavancin is developed for the treatment of complicated skin and skin structure infections (cSSSIs), predominantly those caused by MRSA and β-hemolytic streptococci , organisms against which it has shown greater potency than existing glycopeptide therapeutic agents. | [in vivo]
Dalbavancin (15-240 mg/kg; intraperitoneal injection; every 36 h or 72 h; for 14 days; female BALB/c mice) treatment has a survival rate of 80% to 100% of mice with all dose regimens. | Animal Model: | Female BALB/c mice (6-8 weeks) challenged with Ames strain of B . anthracis | | Dosage: | 15 mg/kg, 30 mg/kg, 60 mg/kg, 120 mg/kg, 240 mg/kg | | Administration: | Intraperitoneal injection ; every 36 h or 72 h; for 14 days | | Result: | The efficacy was 80 to 100%, as determined by the rate of survival at 42 days, when treatment was initiated 24 h postchallenge with regimens of 15 to 120 mg/kg every 36 h or 30 to 240 mg/kg every 72 h. | | [IC 50]
Glycopeptide | [storage]
Store at -20°C | [References]
[1] Heine HS, et al. Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model. Antimicrob Agents Chemother. 2010 Mar;54(3):991-6. DOI:10.1128/AAC.00820-09
[2] Bennett JW, et al. Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review. Ther Clin Risk Manag. 2008 Feb;4(1):31-40. DOI:10.2147/tcrm.s46 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|